Total synthesis of the protected aglycon of fidaxomicin (Tiacumicin B, Lipiarmycin A3) by Miyatake-Ondozabal, Hideki et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Total synthesis of the protected aglycon of fidaxomicin (Tiacumicin B,
Lipiarmycin A3)
Miyatake-Ondozabal, Hideki; Kaufmann, Elias; Gademann, Karl
Abstract: Fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is a novel macrocyclic antibiotic
that is used in hospitals for the treatment of Clostridium difficile infections. This natural product has
also been shown to have excellent bactericidal activity against multidrug-resistant Mycobacterium tuber-
culosis. In spite of its attractive biological activity, no total synthesis has been reported to date. The
enantioselective synthesis of the central 18-membered macrolactone is reported herein. The key reactions
include ring-closing metathesis between a terminal olefin and a dienoate moiety for macrocyclization, a
vinylogous Mukaiyama aldol reaction, and a Stille coupling reaction of sterically demanding substrates.
The retrosynthesis involves three medium-sized fragments, thus leading to a flexible yet convergent syn-
thetic route.
DOI: https://doi.org/10.1002/anie.201409464
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-138850
Accepted Version
Originally published at:
Miyatake-Ondozabal, Hideki; Kaufmann, Elias; Gademann, Karl (2015). Total synthesis of the protected
aglycon of fidaxomicin (Tiacumicin B, Lipiarmycin A3). Angewandte Chemie Internationale Edition,
54(6):1933-1936.
DOI: https://doi.org/10.1002/anie.201409464
COMMUNICATION          
 
 
 
 
Total Synthesis of the Protected Aglycon of Fidaxomicin 
(Tiacumicin B, Lipiarmycin A3) 
Hideki Miyatake-Ondozabal, Elias Kaufmann and Karl Gademann* 
Dedication ((optional)) 
Abstract: Fidaxomicin, also known as tiacumicin B or lipiarmycin A3, 
is a novel macrocyclic antibiotic used in hospitals for the treatment of 
Clostridium difficile infections. This natural product has also been 
shown to have an excellent bactericidal activity against multi-drug 
resistant Mycobacterium tuberculosis. In spite of its attractive 
biological activity, no total synthesis has ever been reported to date. 
Herein, we report the enantioselective synthesis of the central 18-
membered macrolactone. The noteworthy reactions include ring-
closing metathesis between a terminal olefin and a dienoate moiety 
for macrocyclization, a vinylogous Mukaiyama aldol reaction, and a 
Stille coupling reaction of sterically demanding substrates. The 
retrosynthesis comprises of three medium sized fragments leading 
to a flexible yet convergent synthetic route. 
Among all the treatable diseases, tuberculosis (TB) still remains 
one of the major public health concerns worldwide.[1] 
Approximately nine million new cases of TB and an estimated 
two million deaths occur each year.[2] Current therapeutic options, 
such as the use of frontline drugs (rifampicin and isoniazid), 
have become limited due to the spread of resistant forms of 
bacteria.[3] Hence, the development of new anti-Mycobacterium 
tuberculosis pharmaceuticals has become an urgent task in the 
present medical research. In this context we became interested 
in fidaxomicin (1, tiacumicin B, lipiarmycin A3),[4] which is a 
bacterial RNA polymerase inhibitor with promising anti-bacterial 
activity against MTB.[1] The molecule is also structurally 
attractive, owning a complex 18-membered aglycon fragment 
with multiple stereogenic centers, two glycosidic linkages where 
the eastern glycoside carries a fully substituted dichloro-
resorcinol unit. Unfortunately, the lack of bioavailability and 
vulnerability of the compound under acidic conditions prohibited 
its use as a therapeutic for TB.[5] Structure modifications either 
by semi- or total synthesis could therefore be crucial operation to 
improve its pharmacokinetic profile. 
 
 
 
 
    
 Currently, this natural product is used in the clinic for the 
treatment of a different disease, namely Clostridium difficile 
infections, and introduced on the market by Optimer 
pharmaceuticals in 2011.[6]  Fidaxomicin has demonstrated 
similar clinical cure rates compared to vancomycin, however it is 
considered to be superior due to its favorable adverse effect 
profile (decreased rates of recurrence). Given its proven 
potential as a pharmaceutical, we started to investigate an 
efficient and convergent total synthesis of fidaxomicin (1) and 
thereby allowing access to structurally diverse analogues with 
appropriate pharmacokinetics for the treatment of TB. It is 
remarkable that no total synthesis has been reported to date 
since its first isolation via fermentation of a strain called 
Actinoplanes deccanensis in 1975, and despite its clinical use as 
a pharmaceutical agent.[7] Up to now, synthetic studies of the 
core aglycon have been documented in a PhD thesis,[8] and 
studies on the carbohydrates,[9,10] and resorcinol[11] parts have 
been reported in the literature. Independent and concomitant 
syntheses of the lipiarmycin A3 macrolactone and a putative 
lipiarmycin aglycon have been carried out by the groups of 
Altmann and Zhu, respectively.[12] 
Scheme 1. Proposed retrosynthesis of the target macrolactone 2. 
In this communication, we report the successful synthesis 
of the central aglycon of fidaxomicin (1) featuring a vinylogous 
Mukaiyama aldol reaction (VMAR), a Stille coupling reaction, 
Yamaguchi esterification, and a ring-closing metathesis (RCM). 
We have established a relatively short and highly convergent 
synthetic route to the macrocycle 2 where our retrosynthetic 
analysis led to three main building blocks, the vinyl iodide 3, the 
vinyl stannane 4 and the dienoic acid 5 (Scheme 1).  
Scheme 2. Synthesis of vinyl iodide fragment 3. a) NaHMDS, THF, −78°C 
then TBSCl, 97%; b) (E)-3-iodo-2-methylacrylaldehyde, TiCl4, CH2Cl2, −78°C 
to −30°C, 47%, d.r. > 20:1; c) para-nitrobenzoic acid, DEAD, PPh3, THF, 
0°C, 78%; d) NaBH4, THF/H2O; e) MnO2, CH2Cl2, 76% (2 steps); f) (−)-
Ipc2B(allyl), Et2O, −78°C then aq. NaBO3, 70%, d.r. = 20:1; g) TBSOTf, 2,6-
lutidine, CH2Cl2, 93%; h) K2CO3, MeOH/H2O; i) TESOTf, 2,6-lutidine, CH2Cl2, 
95% (2 steps). DEAD: diethyl azodicarboxylate, HMDS: 
hexamethyldisilazane, Ipc: isopinocampheyl, PNB: para-nitrobenzyl, TBS: 
tert-butyldimethylsilyl, TES: triethylsilyl, THF: tetrahydrofuran. 
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The synthesis started with the preparation of silyl ketene N,O-
acetal 7 via g-deprotonation and O-tert-butyldimethylsilylation of 
the known building block 6 (Scheme 2).[13] The subsequent anti-
selective VMAR[14] was performed between 7 and freshly 
prepared (E)-3-iodo-2-methylacrylaldehyde in the presence of 
TiCl4 as a Lewis acid. In search of the best reaction conditions, 
we found that a higher reaction concentration led to highest yield 
and diastereoselectivity (47%, d.r. > 20:1) with 35% recovery of 
desilylated starting material 6. To the best of our knowledge, this 
transformation represents the first example of a VMAR, 
developed by Kobayashi et al., [14] where a different substituent 
(ethyl group in our case) has been utilized as opposed to the 
standard methyl group. In order to obtain the desired syn-
configured product, a Mitsunobu inversion was carried out to 
give ester 9 in 78% yield.[15] The selective cleavage of Evans 
auxiliary[16a] over the PNB-ester was achieved under reducing 
conditions[16b] and the subsequent allylic oxidation with MnO2 
gave the a,b-unsaturated aldehyde 10 in 76% yield over two 
steps. The absolute configuration of the product was 
unambiguously confirmed by a single crystal X-ray 
crystallographic analysis of its vinyl bromide derivative. The next 
step involved a diastereoselective Brown allylation of aldehyde 
10 with (-)-allyl-diisopinocampheylborane.[17] A high 
diastereoselectivity of 20:1 was observed along with acceptable 
yield of 70%. The TBS-protection of the allylic alcohol 11 
furnished silyl-ether 12 (93%). Subsequent exchange of the 
protecting groups from benzoylester to silylether (95% over two 
steps) turned out to be an essential manipulation to accomplish 
the successful cross-coupling reaction. 
 
 
 
 
 
 
Scheme 3. Synthesis of vinyl stannane fragment 4. a) TBSCl, Imid, CH2Cl2, 
93%; b) propyne, n-BuLi, BF3Et2O, THF, −78°C to 0°C, 90%; c) Pd(OAc)2, 
PCy3, Bu3SnH, hexane, 51%. Imid: imidazole, Cy: cyclohexyl. 
 
The southern building block of the macrolactone was prepared 
in three synthetic steps (Scheme 3). The synthesis began with a 
silyl-etherification[18] of a known chiral epoxy alcohol 13 (93%, e.e. 
> 99:1), accessible via a kinetic resolution of 3-buten-2-ol using 
Sharpless epoxidation.[19] Regioselective epoxide opening[20] 
using propynyllithium and boron trifluoride diethyl etherate was 
followed by Pd-catalyzed hydrostannylation to give the 
secondary alcohol 4 in 46% yield over two steps. During the 
course of hydrostannlylation, the formation of undesired regio-
isomer could not be supressed, thus leading to only moderate 
yield. Other approaches such as hydrozirconation[21] and stannyl-
cupration[22] gave complex mixtures of products. 
 
 
Scheme 4. Synthesis of dienoic acid fragment 5. a) LDA (3.5 equiv), THF, 
−78°C then acrolein, −78°C; b) Me2SnCl2 (10 mol%), TBSCl, Et3N, 75% (2 
steps); c) Ac2O, Et3N, DMAP, CH2Cl2; d) DBU, CH2Cl2, 72% (2 steps), E:Z = 
5.5:1; e) DIBAH, CH2Cl2, −10°C; f) MnO2, CH2Cl2; g) NaClO2, KH2PO4, 2-
methyl-2-butene, t-BuOH/H2O, 70% (3 steps). LDA: lithium diisopropylamide, 
DBU: 1,8-diazabicycloundec-7-ene, DIBAH: diisobutylaluminium hydride, 
DMAP: 4-dimethylaminopyridine. 
 
The final building block 5 constitutes for the eastern part of the 
macrolactone, incorporating the dienoic acid moiety (Scheme 4). 
Firstly, commercially available ethyl 3-hydroxypropanoate (15) 
was treated with excess of lithium diisopropylamide and reacted 
with acrolein to furnish the corresponding aldol product. Next, 
the mono-selective tert-butyldimethylsilylation mediated by 
dimethyltin dichloride[23] was followed by acetylation and base 
induced E1cb-elimination to give the dienoate 16 in 54% over four 
steps (d.r. = 5.5:1). Finally, formal hydrolysis (DIBAH reduction, 
allylic and Lindgren-Pinnick oxidations) of ester 16 was executed 
to give the corresponding carboxylic acid 5 in 70% yield over 
three steps. It is worth mentioning that the standard hydrolysis 
conditions using either lithium hydroxide or sodium hydroxide led 
to desilylation as a major side reaction. 
Scheme 5. Synthesis of bis-silyl protected aglycon 2. a) 4, CuTC, Pd[PPh3]4, 
[Bu4N]+[Ph2PO2]-, DMF, 77%; b) 5, Cl3C6H2COCl, Et3N, DMAP, PhMe, 86%; c) 
Grubbs cat. II (15 mol%), PhMe, 40°C (μw), 10min, E:Z = 2:3, then 100°C, 
18h, E:Z = 2:1, 90%; d) Grubbs cat. II (15 mol%), PhMe, 100°C, 18h, E:Z = 
2:1, 92%; e) HFEt3N, THF/MeCN 1:1, 0°C to 23°C, 2:65%, 20:32%. CuTC: 
copper(I) thiophene-2-carboxylate, DMF: dimethylformamide.  
 
With the three building blocks 3, 4 and 5 in hand, we focused 
our attention to the Stille coupling step. As anticipated, this 
transformation was experimentally challenging due to the 
sterically damanding nature of both vinyl iodide and stannane 
fragments. After screening of several reaction conditions, we 
were delighted to find the optimal conditions using a combination 
of copper thiophene-2-carboxylate (CuTC)[24] and [Pd(PPh3)4] in 
the presence of tetrabutylammonium diphenylphosphonate 
salt,[25]  giving the diene 17 in very high yield of 77% (Scheme 5). 
In this step, the only significant side reaction was the self-
dimerization of the vinyl iodide 3 (~10%). These unique yet 
effective conditions have been reported by Fürstner and co-
workers and a series of hindered substrates have been 
successfully cross-coupled.[26] The resulting secondary alcohol 
17 was then efficiently acylated with dienoic acid 5 under 
Yamaguchi esterification[27] conditions to give ester 18 in 86% 
yield. Pleasingly, the subsequent RCM[28] of olefin 18 proceeded 
smoothly utilizing the second generation Grubbs catalyst (15 
mol%) to give a mixture of E:Z macrocycles in a overall yield of 
90%. Both the initiation and conversion of this transformation 
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could be observed to be extremely fast and it could be 
conducted even at room temperature, intriguingly giving only the 
Z-isomer 19 in this case. At 40°C, full conversion was observed 
within 10 minutes with E:Z ratio of 2:3 and further improvement 
to ratio of 2:1 was possible through isomerization at elevated 
temperature. Interestingly the fact that the isomerization was not 
observed in the absence of the catalyst, the thermodynamic 
equilibrium is most likely reached through ring-opening and 
closing events. Fortunately, the two isomers were separable by 
column chromatography, which in turn allowed recycling of Z-
isomer to isomerization conditions giving 80% yield of E-isomer 
19 after one cycle. The final selective deprotection of primary 
TBS-ether and secondary TES-ether were achieved using 
triethylamine trihydrofluoride in 65% yield. In order to avoid 
unwanted over-deprotection, the reaction had to be stopped 
after a certain time allowing the isolation of TES-ether 
deprotected intermediate 20 (32%), which could be recycled to 
give more of the desired diol 2. The aglycon 2 fulfills the criteria 
as a key building block for the completion of the total synthesis, 
having the appropriate free hydroxyl groups for the following 
glycosylations. 
    
    In summary, we report the preparation of the protected 
aglycon of fidaxomicin (1). The target macrocycle 2 was 
successfully synthesized in 14 steps (longest linear sequence) 
through three main fragments, allowing considerable amount of 
flexibility in exploring the points of diversity for analogue 
synthesis. The highlights of our strategy include the RCM 
between a terminal olefin and a dienoate moiety for 
macrocyclization, a diastereoselective VMAR, and a Stille 
coupling reaction of sterically hindered substrates. Currently, the 
total synthesis of the natural product including the preparations 
of noviose, rhamnose, and resorcinol units as well as 
glycosylation studies are in progress in our group and will be 
reported in due course. 
Keywords: Natural products • antibiotics • cross coupling • 
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